- Home
- URGN vs IVR Comparison
URGN vs IVR Comparison
Compare URGN & IVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- IVR
- Stock Information
- Founded
- URGN 2004
- IVR 2008
- Country
- URGN United States
- IVR United States
- Employees
- URGN N/A
- IVR N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- IVR Real Estate Investment Trusts
- Sector
- URGN Health Care
- IVR Real Estate
- Exchange
- URGN Nasdaq
- IVR Nasdaq
- Market Cap
- URGN 547.1M
- IVR 481.9M
- IPO Year
- URGN 2017
- IVR 2009
- Fundamental
- Price
- URGN $11.19
- IVR $8.21
- Analyst Decision
- URGN Strong Buy
- IVR Buy
- Analyst Count
- URGN 5
- IVR 3
- Target Price
- URGN $44.50
- IVR $8.00
- AVG Volume (30 Days)
- URGN 456.4K
- IVR 1.3M
- Earning Date
- URGN 11-06-2024
- IVR 11-05-2024
- Dividend Yield
- URGN N/A
- IVR 19.51%
- EPS Growth
- URGN N/A
- IVR N/A
- EPS
- URGN N/A
- IVR 1.23
- Revenue
- URGN $89,363,000.00
- IVR $102,893,000.00
- Revenue This Year
- URGN $14.43
- IVR N/A
- Revenue Next Year
- URGN $44.44
- IVR $2.72
- P/E Ratio
- URGN N/A
- IVR $6.67
- Revenue Growth
- URGN 15.64
- IVR 654.96
- 52 Week Low
- URGN $10.60
- IVR $7.60
- 52 Week High
- URGN $20.70
- IVR $9.97
- Technical
- Relative Strength Index (RSI)
- URGN 35.94
- IVR 41.27
- Support Level
- URGN $11.93
- IVR $8.20
- Resistance Level
- URGN $12.78
- IVR $8.52
- Average True Range (ATR)
- URGN 0.71
- IVR 0.21
- MACD
- URGN -0.05
- IVR 0.02
- Stochastic Oscillator
- URGN 1.36
- IVR 60.33
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.